![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis
|
|
|
Reported by Jules Levin
Infectious Disease Week
October 8-12, 2014
Philadelphia, PA
C Brinson,1 J Lalezari,2 GH Latiff,3 M Thompson,4 J Echevarrķa,5
S Trevino-Perez,6 D Stock,7 SR Joshi,7 GJ Hanna,8 M Lataillade7
for the AI438011 study team
1Central Texas Clinical Research, Austin, TX, USA; 2. Quest Clinical Research, San Francisco, CA, US; 3. Maxwell Clinic, Durban, South Africa; 4. AIDS Research Consortium of Atlanta, Atlanta, USA; 5. Hospital Nacional Cayetano Heredia, Lima, Peru; 6. Mexico Centre for Clinical Research, Mexico City, Mexico; 7. Bristol-Myers Squibb, Wallingford, CT, USA; 8. Bristol-Myers Squibb, Princeton, NJ, USA.
![IDSA1.gif](../images/101014/101014-5/IDSA1.gif)
![IDSA2.gif](../images/101014/101014-5/IDSA2.gif)
![IDSA3.gif](../images/101014/101014-5/IDSA3.gif)
![IDSA4.gif](../images/101014/101014-5/IDSA4.gif)
![IDSA5.gif](../images/101014/101014-5/IDSA5.gif)
![IDSA6.gif](../images/101014/101014-5/IDSA6.gif)
![IDSA7.gif](../images/101014/101014-5/IDSA7.gif)
![IDSA8.gif](../images/101014/101014-5/IDSA8.gif)
![IDSA9.gif](../images/101014/101014-5/IDSA9.gif)
![IDSA10.gif](../images/101014/101014-5/IDSA10.gif)
![IDSA11.gif](../images/101014/101014-5/IDSA11.gif)
![IDSA12.gif](../images/101014/101014-5/IDSA12.gif)
![IDSA13.gif](../images/101014/101014-5/IDSA13.gif)
![IDSA14.gif](../images/101014/101014-5/IDSA14.gif)
![IDSA15.gif](../images/101014/101014-5/IDSA15.gif)
![IDSA16.gif](../images/101014/101014-5/IDSA16.gif)
![IDSA17.gif](../images/101014/101014-5/IDSA17.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|